MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive: For instance, constitutive activation of the pathway is also observed independent of activating mutations in solid and hematopoietic malignancies, including CML, in which the BCR-ABL fusion oncoprotein (which drives the pathology) is responsible for ERK1/2 activation.